$1.39
-0.015[-1.07%]
At close: Apr 29
$1.39
0[0.00%]
PreMarket: 5:30AM EDT
Marinus Pharma
(NASDAQ:MRNS)Marinus Pharma Stock (NASDAQ:MRNS), Analyst Ratings, Price Targets, Predictions
Marinus Pharmaceuticals Inc has a consensus price target of $15.5, established from looking at the 38 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Baird, and HC Wainwright & Co. on April 17, 2024, April 16, 2024, and April 16, 2024. With an average price target of $13 between Truist Securities, Baird, and HC Wainwright & Co., there's an implied 835.25% upside for Marinus Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Baird
HC Wainwright & Co.
RBC Capital
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Marinus Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 619.42% | Truist Securities | Joon Lee | $25 → $10 | Maintains | Buy | Get Alert |
| 04/16/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 43.88% | Baird | Brian Skorney | $20 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 04/16/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1842.45% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
| 04/15/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 115.83% | RBC Capital | Brian Abrahams | $24 → $3 | Downgrade | Outperform → Sector Perform | Get Alert |
| 04/10/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1914.39% | Cantor Fitzgerald | Charles Duncan | → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 03/26/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1842.45% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 547.48% | Oppenheimer | Jay Olson | $9 → $9 | Maintains | Perform | Get Alert |
| 03/06/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1626.62% | RBC Capital | Brian Abrahams | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1842.45% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1842.45% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1698.56% | Truist Securities | Joon Lee | $32 → $25 | Maintains | Buy | Get Alert |
| 09/21/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1914.39% | Cantor Fitzgerald | Charles Duncan | → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1410.79% | RBC Capital | Brian Abrahams | $20 → $21 | Maintains | Outperform | Get Alert |
| 09/20/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1842.45% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1842.45% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1338.85% | RBC Capital | Brian Abrahams | $21 → $20 | Maintains | Outperform | Get Alert |
| 08/11/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 2202.16% | Truist Securities | Joon Lee | $42 → $32 | Maintains | Buy | Get Alert |
| 08/11/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 835.25% | Ladenburg Thalmann | Michael Higgins | $17 → $13 | Maintains | Buy | Get Alert |
| 08/11/2023 | MRNS | Buy Now | Marinus Pharma | $1.39 | 1338.85% | Baird | Brian Skorney | $24 → $20 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Marinus Pharma (MRNS)?
The latest price target for Marinus Pharma (NASDAQ: MRNS) was reported by Truist Securities on April 17, 2024. The analyst firm set a price target for $10.00 expecting MRNS to rise to within 12 months (a possible 619.42% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Marinus Pharma (MRNS)?
The latest analyst rating for Marinus Pharma (NASDAQ: MRNS) was provided by Truist Securities, and Marinus Pharma maintained their buy rating.
When was the last upgrade for Marinus Pharma (MRNS)?
There is no last upgrade for Marinus Pharma.
When was the last downgrade for Marinus Pharma (MRNS)?
The last downgrade for Marinus Pharmaceuticals Inc happened on April 16, 2024 when Baird changed their price target from $20 to $2 for Marinus Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Marinus Pharma (MRNS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Marinus Pharma (MRNS) correct?
While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a maintained with a price target of $25.00 to $10.00. The current price Marinus Pharma (MRNS) is trading at is $1.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.